To compare the performance of population-based kinetics with that of directly measured C-peptide kinetics when used to calculate β-cell responsivity indices, and to study people with and without acute insulin resistance to ensure that population-based kinetics apply to all conditions where β-cell function is measured.
| INTRODUCTION
Defects in insulin secretion are central to the pathogenesis of type 2 diabetes, and are evident early in the development of impaired glucose tolerance and the subsequent transition to type 2 diabetes. 1 As such, accurate and reproducible measurement of insulin secretion is central to understanding disorders of glucose metabolism as well as to quantifying the effect of therapies or other interventions on β-cell function. 2 The Disposition Index (DI) 2 expresses insulin secretion as a function of the prevailing insulin action and is accepted as a reliable measure of β-cell function, 3 producing consistent results in response to different oral challenges. 4 Unfortunately, measurement of insulin concentrations before and after a stimulus to β-cell secretion does not accurately reflect insulin secretion into the portal vein because insulin undergoes hepatic extraction prior to its appearance in the systemic circulation. 5 Because of this, peripheral insulin concentrations reflect the net sum of two processes: insulin secretion and hepatic extraction. 2 Indeed, there is evidence that the fraction of insulin extracted across the liver is altered by changes in β-cell function (measured using the DI), 6 or by insulin secretory burst mass during euglycaemia or hyperglycaemia 7 ; therefore, differences in hepatic insulin clearance introduce a systematic error in measures based on peripheral insulin concentrations when comparing groups with differing β-cell function. 6 C-peptide is co-secreted in an equimolar ratio with insulin and does not undergo hepatic extraction 8 ; therefore, C-peptide concentrations in the peripheral circulation would theoretically be more representative of insulin secretion by the β cell. The half-lives of insulin and C-peptide in the circulation, however, differ dramatically so that C-peptide accumulates in the circulation compared with insulin. 9 Because the circulating concentration of a hormone or substrate represents the balance between secretion and clearance, estimating the rate of insulin secretion from C-peptide concentrations requires knowledge of C-peptide clearance.
In a previous study, we 10 and others 11 have used measures of β-cell function that depend on the deconvolution of insulin secretion rates from C-peptide concentrations in the systemic circulation.
These methods incorporate age-associated changes in C-peptide kinetics that were directly measured in an experiment undertaken by
Van Cauter et al. 12 in 200 people, including people with type 2 diabetes and obesity. Subsequently, these data were used to measure 24-hour profiles of insulin secretion in 36 people. Toffolo et al. 13 validated this methodology by directly comparing these standardized estimates with individually measured C-peptide kinetics and the effect of these differences on the estimates of β-cell function during an intravenous glucose tolerance test (IVGTT). The authors concluded that the population-based variables as proposed by Van Cauter et al. 12 allow accurate estimates of β-cell function during an IVGTT in 7 subjects. The time course of insulin secretion in response to an intravenous challenge (IVGTT) differs significantly from that of an oral challenge. 14 Indeed measurement of β-cell responsivity in prediabetes using IVGTTs and OGTTs can produce discordant results. 3 It is currently unknown if population-based and individually assessed C-peptide kinetics provide comparable assessment of indices of β-cell function in response to an oral challenge because a validation similar to that performed by Toffolo et al. 13 has not been undertaken. For a full discussion of the methodology see Cobelli et al. 
| Participants
The participants in the present study represent a subset of those who participated in a series of previously published experiments intended to examine the role of the diabetes-associated genotype at the TCF7L2 locus in the pathogenesis of prediabetes. 10, 15 After approval from the Mayo Clinic institutional review board, we identified suitable participants who provided written, informed consent. At the time of screening, body composition was measured using dualenergy X-ray absorptiometry (iDXA scanner; GE, Wauwatosa, Wisconsin).
| Experimental design: clamp experiment
On 1 study day, participants underwent a euglycaemichyperinsulinaemic clamp over a 375-minute period. The first part of the experiment (0-240 minutes) has been described previously. 
| Experimental design: oral glucose challenge in the presence or absence of acute insulin resistance
The experimental design has been described previously. 10, 15 Briefly, participants were initially studied on two occasions in random order, 2 weeks apart. On one occasion, participants received an infusion of Intralipid and heparin to raise FFA concentrations, while on the other occasion, glycerol was infused at a rate of 5 μmol/kg/min (to match the amount of glycerol present in the Intralipid infused during the FFA study day). The infusions commenced 3 hours before challenge with a glucose drink (1 g per kg body weight) and were continued until the end of study (6 hours after the start of the meal). Blood samples were obtained at periodic intervals for hormone and substrate measurement over the course of the experiment.
| Analytical techniques
Glucose concentrations were measured using a glucose oxidase method (Yellow Springs Instruments, Yellow Springs, Ohio). Plasma insulin was measured using a chemiluminescence assay (Access Assay; Beckman, Chaska, Minnesota). Plasma glucagon and C-peptide
were measured by Radio-Immunoassay (Linco Research, St. Louis, Missouri).
| Calculations
Data are presented as means AE standard error of the mean (s.e.m.).
We used a 2-compartment model of C-peptide kinetics, where the relevant kinetic indices were estimated using anthropometric data as previously described. 12 The population-based C-peptide kinetics were then used to estimate insulin secretion and subsequent β-cell responsivity during the oral challenges. 12 Separately, observed C-peptide decay curves were used to estimate the kinetic parameters of C-peptide 16 in each participant after bolus injection when endogenous secretion is inhibited, using a maximum a posteriori (MAP) estimation. 17, 18 The resulting parameters were then used to derive the β-cell responsivity indices during the oral glucose challenge (on both the glycerol and FFA study days) using the oral C-peptide minimal model. 19 The oral C-peptide minimal model assumes that insulin secretion comprises static and dynamic components. The static component, which is proportional, through the variable Ф s , to the delayed glucose concentration, represents the provision of new insulin to the releasable pool. The dynamic component is proportional, through the variable Ф d , to the rate of increase of glucose concentrations. An index of total β-cell responsivity to glucose (Ф) is then derived from both indices. 20 Net insulin action (S i ) was measured using the oral minimal model as previously described. 21 DIs were subsequently calculated by multiplying the relevant β-cell responsivity indices (Ф d , Ф s and Φ)
by S i .
| Statistics
Data are presented as mean AE s.e.m. The primary analysis compared individual indices of β-cell responsivity obtained using either population-based or individually derived C-peptide clearance. The between-group differences in indices of β-cell responsivity, obtained using either population-based or individually derived C-peptide kinetics, were examined using a paired, 2-tailed t-test or a signed-rank test, as warranted by their distribution. In addition, to better understand intra-individual differences, we calculated the percentage differences for kinetic variables and DIs for each individual, derived using individually measured or population-based data using the formula:
To characterize the sensitivity of individual variation in DI to each of the kinetic variables (k 01 , k 12 and k 21 ), we identified the C-peptide minimal model 3 times for every individual. For each identification, we fixed 2 of the kinetic variables to their individually measured values and the third to its population value. We then calculated the sensitivity of DI to that variable using the following formula:
where k ij represents one of the coefficients k 01 , k 12 and k 21 .
Statistical analysis was performed in PRIMER 5 (GraphPad Software, San Diego, California). Bland-Altman plots (absolute difference vs average values) were used to examine differences in indices calculated using the different methods of estimating C-peptide clearance.
A multivariate analysis performed in JMP Pro 11 (SAS, Cary, North could not be explained by age, sex or weight (data not shown).
| Comparison of intra-individual differences in DI d
, DI s and DI, calculated using population-based and individually measured C-peptide clearance during glycerol infusion or FFA elevation
The % intra-individual difference in DI d did not differ during the glycerol and FFA study days (17% AE 2% vs 24% AE 3%; P = .11
[ Figure 4A ]). The same was true for DI s (15% AE 2% vs 16% AE 2%; P = .32 [ Figure 4B ]) and DI (16% AE 2% vs 16% AE 2%; P = .38
[ Figure 4C] ).
3.6 | Sensitivity of DI to intra-individual differences in kinetic measures of C-peptide clearance during glycerol infusion or FFA elevation
The sensitivity of DI to k 01 did not differ between study days (92% AE 17% vs 104% AE 17%; P = .10 [ Figure 5A ]), but was much higher than for the other kinetic variables. The sensitivity of DI to k 12
(9% AE 1% vs 12% AE 2%; P = .55 [ Figure 5B ]) also did not differ between study days. The sensitivity of DI to k 21 did not differ between study days and was even lower (7% AE 2% vs 5% AE 1%; P = .14 [ Figure 5C ]).
| DISCUSSION
We report that, in general, indices of β-cell responsivity to oral glucose calculated using population-based kinetics correlated well with those derived using individually measured C-peptide kinetics. Taken together, these data imply that the use of population-based C-peptide kinetics enables reliable estimation of β-cell function in response to an oral challenge even in situations where insulin action is decreased acutely. This is because DI is relatively insensitive to errors in the estimation of k 12 and k 21 , but sensitive to errors in the estimation of k 01 . This was to be expected to some extent as this variable k 01 translates the fractional clearance rate of C-peptide. A large error in this variable translates into a large error in insulin secretion rate and thus in the β-cell responsivity index (Φ) and DI 2 ; however, the differences between parameters calculated by either method are lowest for k 01 , explaining the good correlation of DI calculated using population kinetics with that calculated using individually measured kinetics.
Measurement of β-cell function using the oral C-peptide minimal model depends on C-peptide kinetics. In previous studies, we 6, 22, 23 and others 24, 25 have used C-peptide kinetics data derived by Van
Cauter et al. 12 whereby C-peptide kinetic variables were estimated from direct measurement in a group of 200 people of varying age, gender, obesity and glucose tolerance. Although measures of β-cell function using alternative methodology (independent of C-peptide concentrations) can correlate well with those dependent on these intravenous glucose challenge (where the approach had been validated independently) 13 differs significantly from that in response to an oral challenge. 26, 27 To ensure an ability to accurately detect insulin pulses in the hepatic venous circulation and in the systemic circulation (as part of a series of studies examining the pathogenesis of prediabetes), we esti- however, these data show that estimation of DI using the oral minimal model is more sensitive to the actual hormone and substrate concentrations used to measure β-cell responsivity than it is to these kinetic variables in otherwise healthy humans; at least in those with intact renal function and demographic characteristics like those of the study population.
Total DI varied by 16% AE 2% depending on whether directly ; however, despite this limitation, indices of β-cell responsivity (and DI) were relatively unaffected by the method used to determine C-peptide kinetics.
The other potential limitation is that the cohort studied was recruited on the basis of participants' TCF7L2 genotype, as previously described. 10 This locus has been associated with type 2 diabetes, 28 impaired insulin secretion 29 and impaired suppression of glucagon 10 ; however, we studied participants with both the TT (diabetes-associated) and the CC (diabetes-protective) genotype at rs7903146 (in the TCF7L2 locus) and there was no evidence of an effect of genotype on C-peptide clearance (data not shown). This concurs with an a priori absence of evidence that this locus alters Cpeptide clearance and has effects on renal function or on hepatic and extra-hepatic insulin action. 15 In this cohort, the genotype at rs7903146 in the TCF7L2 locus did not alter the relationship between indices calculated using individually determined C-peptide clearance vs those using population-based data, on either study day (data not shown).
Taken together, these data support the application of population-based measures of C-peptide kinetics to the measurement of β-cell function using the oral minimal model in people without diabetes who have normal renal function.
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